DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213423

Clinical profile and risk factors associated in patients of mucormycosis in COVID-19 pandemic: a study in a tertiary centre

M. Anas, R. K. Choudhary, Noman Alam

Abstract


Background: The objective of this study was to determine the clinical profile and risk factors associated in patients of mucormycosis in COVID-19 pandemic.

Methods: It was a prospective observational study conducted at a tertiary care centre in the month of May and June 2021. It involved all patients of mucormycosis mainly involving paranasal sinuses and orbit. The clinical profile and associated risk factors leading to mucormycosis were studied.

Results: Thirty patients of mucormycosis mean age 56.62 years out of them 25 (83.33%) male and 5 (16.66%) female were studied. Twenty-four patients (80%) had COVID-19 infection, out of them 7 (29.2%) were active and 17 (70.8%) had recovered within 4 weeks. Five (16.6%) patients were suspected as they had symptoms of COVID-19 previously   but never got tested. One   patient had no history of COVID infection. All the patients were diabetic at the time of presentation, out of them 26 (86.6%) of patients were known diabetic and 4 (13.3%) became diabetic after COVID-19 infection. The ethmoids were the most common sinuses affected. Intra-orbital extension was seen in 13 (43.3%) of cases   while intracranial extension was seen in 4 (13.3%) patients. Twenty-eight (93.3%) patients gave history of steroids intake. Antibiotics were taken by 76.6% patients while zinc supplement was used by 83.3% patients. Oxygen was used 10 (33.3%) patients, 80% of them using face mask or canula and 4 of them requiring mechanical ventilatory support.  

Conclusions: The risk factors associated with mucormycosis in COVID pandemic must be given serious consideration as there is sudden increase in the case and mortality is very high. Uncontrolled diabetes and over use of steroids in COVID management are two main aggravating factors, however other factors must also be studied thoroughly.


Keywords


Mucormycosis, COVID-19, Pandemic, Diabetes, Steroids, Oppurtunistic

Full Text:

PDF

References


Wuhan City Health Committee. Wuhan Municipal Health and Health Commission’s briefing on the current pneumonia epidemic situation in our city, 2019. Available at: http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989. Accessed on 20 June 2021.

Ribes JA, Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301.

Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25(4):215-29.

Skiada A, Pavleas I, Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An Update. J Fungi. 2020;6(4):265.

Chander J, Kaur M, Singla N, Punia RPS, Singhal SK, Attri AK, et al. Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India. J Fungi. 2018;4(2):46.

Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi. 2019;5(1):26.

Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34.

Maartens G, Wood MJ. The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother. 1991;28:13-22.

Scheckenbach K, Cornely O, Hoffmann TK, Engers R, Bier H, Chaker A, etal. Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx. 2010;37(3):322-8.

Vairaktaris E, Moschos MM, Vassiliou S, Baltatzis S, Kalimeras E, Avgoustidis D, et al. Orbital cellulitis, orbital subperiosteal and intraorbital abscess: report of three cases and review of the literature. J Craniomaxillofac Surg. 2009;37(3):132-6.

Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses. 2007;50(4):290-6.

Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses. 2007;50(4):290-6.

Shazo RD, Chapin K, Swain RE. Fungal sinusitis. N Engl J Med. 1997;337(4):254-9.

Gillespie MB, Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am. 2000;33(2):323-34.

Ballester D, García R, García C, Laza L, Gil F. Mucormycosis of the head and neck: report of five cases with different presentations. J Craniomaxillofac Surg. 2012;40(7):584-91.

Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017;43(12):1751-63.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81.

Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18(1):1-10.

Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. 2003;349(5):507-8.

Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020;12(9):10726.

Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020;185(4):599-606.

Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264-5.

White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020:1298.

Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020;71(9):2459-68.

Bala K, Chander J, Handa U, Punia RS, Attri AK. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol. 2015;53(3):248-57.

Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395-402.

John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi. 2021;7(4):298.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.

Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathog. 2017;13(8):1006408.

Wilson D, Citiulo F, Hube B. Zinc exploitation by pathogenic fungi. PLoS Pathog. 2012;8(12):1003034.